Materias dentro de su búsqueda.
Mostrando 181 - 200 Resultados de 110,380 Para Buscar '"Lu'an"', tiempo de consulta: 1.01s Limitar resultados
  1. 181
    “…BACKGROUND: The [(177)Lu]Lu-DOTA-TATE mediated peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) is sometimes leading to treatment resistance and disease recurrence. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    First preclinical evaluation of [(225)Ac]Ac-DOTA-JR11 and comparison with [(177)Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
  2. 182
    “…INTRODUCTION: [(177)Lu]Lu-PSMA-617 (Lu-PSMA) radioligand therapy is an emerging treatment option for patients with end-stage prostate cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [(177)Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
  3. 183
    “…In this study, we report the efficacy and safety of [(225)Ac]Ac-PSMA-617 augmented [(177)Lu]Lu-PSMA-617 RLT in (177)Lu-naive mCRPC patients (n = 15) with poor prognosis (presence of visceral metastases, high total tumor burden with diffuse bone metastases or a short PSA doubling time of <2 months). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy and Safety of [(225)Ac]Ac-PSMA-617 Augmented [(177)Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
  4. 184
    “…(177)Lu-rhPSMA-10.1 is a novel PSMA-targeting radiopharmaceutical that has been optimized in terms of pharmacological and pharmacokinetic properties and may be therefore advantageous in treatment of metastatic castrate-resistant prostate cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    (177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T
  5. 185
    “…The tolerability of adding [(177)Lu]Lu-PSMA-617 will be evaluated using a Bayesian Optimal Interval (BOIN) dose-escalation design. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Tolerability of concurrent external beam radiotherapy and [(177)Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study (PROQURE-I trial)
  6. 186
    “…This translational research aimed to determine the efficacy and safety of (177)Lu-iPSMA and (177)Lu-DOTATOC developed as GMP pharmaceutical formulations for treating progressive and advanced mCRPC and NET. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using (177)Lu-iPSMA and (177)Lu-DOTATOC: Experience after 905 Treatment Doses
  7. 187
    “…BACKGROUND: Prediction of [(177)Lu]Lu-HA-DOTATATE kidney and tumor uptake based on diagnostic [(68)Ga]Ga-HA-DOTATATE imaging would be a crucial step for precision dosing of [(177)Lu]Lu-HA-DOTATATE. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Predicting [(177)Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [(68)Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
  8. 188
    por Simura, Rayko, Yamane, Hisanori
    Publicado 2020
    “…A single crystal of Ba(0.9)Ce(0.1)LuAl(0.2)Si(3.8)N(6.9)O(0.1) (barium cerium lutetium aluminosilicate nitride oxide) was obtained by heating a mixed powder of Ba(3)N(2), Si(3)N(4), Al, Lu(2)O(3), and CeO(2) at 2173 K for 1 h under N(2) gas at 0.85 MPa. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Lu-atom-ordered oxonitridoaluminosilicate Ba(0.9)Ce(0.1)LuAl(0.2)Si(3.8)N(6.9)O(0.1)
  9. 189
    “…The new construct, ABY-271 with DOTA conjugated at the back of ABD, has been labelled with (177)Lu. Targeting properties of (177)Lu-ABY-271 and (177)Lu-ABY-027 were compared directly. (177)Lu-ABY-271 specifically accumulated in SKOV-3 xenografts in mice. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody(®) Molecules (177)Lu-ABY-271 and (177)Lu-ABY-027: Impact of DOTA Position on ABD Domain
  10. 190
    “…Peptide receptor radionuclide therapy (PRRT) relies on α- and β-emitting radionuclides bound to a peptide that commonly targets somatostatin receptors (SSTRs) for the localized killing of tumors through ionizing radiation. A Lutetium-177 ((177)Lu)-based probe linked to the somatostatin analog octreotate ([(177)Lu]Lu-DOTA-TATE) is approved for the treatment of certain SSTR-expressing tumors and has been shown to improve survival. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Combination of [(177)Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model
  11. 191
    “…ABSTRACT: Baseline uptake on prostate-specific membrane antigen (PSMA)-targeted imaging is a prerequisite for radioligand therapy (RLT) with [(177)Lu]Lu-PSMA-617. This study aims to quantify lesion-based response to RLT in relation to pretreatment standard molecular imaging metrics derived from [(68)Ga]Ga-PSMA-11 PET/CT. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Baseline [(68)Ga]Ga-PSMA-11 PET/CT before [(177)Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
  12. 192
    por Nédélec, R, Vianden
    Publicado 2005
    “…We have studied the implantation behaviour of the rare earth Lu in ZnO. Our samples were implanted at the ISOLDE facility at CERN. …”
    Enlace del recurso
    Enlace del recurso
    Temperature dependent PAC studies with the rare earth '$^{172}$Lu' in ZnO
  13. 193
    “…Non-stoichiometric $Lu_{3+x}Al_{5}O_{12}:Ce$ ($Lu_{3+x}$AG:Ce, x=1, 2, 3 and 4 %) ceramics were fabricated by solid state reaction method and further optimized by an air-annealing process. …”
    Enlace del recurso
    Enlace del recurso
    Optical, luminescence and scintillation characteristics of non-stoichiometric LuAG:Ce ceramics
  14. 194
    “…This work presents a theoretical study of the laser cooling feasibility of the molecule LuF, in the fine structure level of approximation. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Laser cooling with intermediate state of spin–orbit coupling of LuF molecule
  15. 195
    “…Here, we perform high-accuracy comparisons between two (176)Lu(+) references using correlation spectroscopy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    (176)Lu(+) clock comparison at the 10(−18) level via correlation spectroscopy
  16. 196
    “…Here, by using a high-pressure and high-temperature synthesis technique, we have obtained nitrogen-doped lutetium hydride (LuH(2±x)N(y)), which has a dark-blue colour and a structure with the space group [Formula: see text] as evidenced by X-ray diffraction. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Absence of near-ambient superconductivity in LuH(2±x)N(y)
  17. 197
    “…RATIONALE: (177)Lu-PSMA ([(177)Lu]Lutetium-PSMA-617) therapy is an effective treatment option for patients with prostate specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer, but still shows a non-responder rate of approximately 30%. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy
  18. 198
    Enlace del recurso
    Texto
    OP Pesticides, Organic Diets, and Children’s Health: Lu et al. Respond
  19. 199
    “…Pracparatum mungo (Lu-Do Huang) is a traditional Chinese functional medicine made from the natural fermentation of mung bean (Lǜ Dòu) mixed with other Chinese medicines. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evaluation of the Antioxidant and Melanogenesis Inhibitory Properties of Pracparatum Mungo (Lu-Do Huang)
  20. 200
    “…To find the exact dosage and its efficiency, this clinical study was performed on the human being, using (177)Lu-EDTMP for MBP palliation. (177)Lu-EDTMP was prepared by Iran, atomic energy organization. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Metastatic Bone Pain Palliation using (177)Lu-Ethylenediaminetetramethylene Phosphonic Acid
Herramientas de búsqueda: RSS